Bibliografía del artículo
1. Bonds MH, Dobson AP, Keenan DC. Disease ecology, biodiversity, and the latitudinal gradient in income. PLoS Biol 10:e1001456, 2012.
2. WHO. Research priorities for Chagas disease, Human African trypanosomiasis and leishmaniasis. Technical report series N° 975. 2012. Available at http://apps.who.int/iris/bitstream/10665/77472/1/WHO_TRS_975_eng.pdf. Accesed on September 01, 2016.
3. D'Orléans-Juste P, Bkaily G, Rae GA. Endothelin and bradykinin: "brothers-in-arms" in Chagas vasculopathies? Br J Pharmacol 165:1330-2, 2012.
4. Roldão JA, Beghini M, Ramalho LS, et al. Comparison between the collagen intensity and mast cell density in the lingual muscles and myocardium of autopsied chronic chagasic and nonchagasic patients. Parasitol Res 111:647-54, 2012.
5. Jia L, Li Y, Xiao C, Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci (Landmark Ed) 17:221-31, 2012.
6. Xu J, Sun Y, Carretero OA, et al. Effects of cardiac overexpression of the angiotensin II type 2 receptor on remodeling and dysfunction in mice post-myocardial infarction. Hypertension 63:1251-9, 2014.
7. Dell'Italia L, Ardell JL. Sympathetic nervous system in the evolution of heart failure. In: Armour JA, Ardell JL (eds.). Basic and Clinical Neurocardiology, New York, Oxford University Press Inc, pp.340-67, 2004.
8. Hardwick JC, Southerland EM, Girasole AE, Ryan SE, Negrotto S, Ardell JL. Remodeling of intrinsic cardiac neurons: effects of B-adrenergic receptor blockade in Guinea pig models of chronic heart disease. Am J Physiol Regul Integr Comp Physiol 303:R950-8, 2012.
9. Mummidi S, Das NA, Carpenter AJ, et al. Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone salt-induced cardiac fibrosis in vivo. J Mol Cell Cardiol 98:95-102, 2016.
10. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease-a perspective. Drug Des Devel Ther 4:383-413, 2010.
11. Aparecida da Silva C, Fattori A, Sousa AL, et al. Determining the C-reactive protein level in patients with different clinical forms of chagas disease. Rev Esp Cardiol 63:1096-9, 2010.
12. Bravo-Tobar ID, Nello-Pérez C, Fernández A, et al. Adenosine deaminase activity and serum c-reactive protein as prognostic markers of Chagas disease severity. Rev Inst Med Trop Sao Paulo 57:385-92, 2015.
13. García-Álvarez A, Sitges M, Heras M, et al. Endothelial function and high-sensitivity C-reactive protein levels in patients with Chagas disease living in a nonendemic area. Rev Esp Cardiol 64:891-6, 2011.
14. López L, Arai K, Giménez E, et al. C-reactive protein and interleukin-6 serum levels increase as Chagas disease progresses towards cardiac failure. Rev Esp Cardiol 59:50-6, 2006.
15. Apt W, Zulantay I. Update on the treatment of Chagas' disease. Rev Med Chil 139:247-57, 2011.
16. Sun W, Zhang H, Guo J, et al. Comparison of the efficacy and safety of different ACE inhibitors in patients with chronic heart failure: A PRISMA-compliant network meta-analysis. Medicine (Baltimore) 95:e2554, 2016.
17. Wu CK, Luo JL, Tsai CT, et al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J 10:46-53, 2010.
18. Batlouni M, Barretto AC, Armaganijan D, et al. Treatment of mild and moderate cardiac failure with captopril. A multicenter study. Arq Bras Cardiol 58:417-21, 1992.
19. Bellabarba G, Davila DF, Torres A, et al. Plasma renin activity in chagasic patients with and without congestive heart failure. Int J Cardiol 47:5-11, 1994.
20. De Paula Costa G, Silva RR, Pedrosa MC, et al. Enalapril prevents cardiac immune-mediated damage and exerts anti-Trypanosoma cruzi activity during acute phase of experimental Chagas disease. Parasite Immunol 32:202-8, 2010.
21. Khoury AM, Davila DF, Bellabarba G, et al. Acute effects of digitalis and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. Int J Cardiol 57:21-9, 1996.
22. Roberti RR, Martinez EE, Andrade JL, et al. Chagas cardiomyopathy and captopril. Eur Heart J 13:966-70, 1992.
23. Szajnbok FE, Barretto AC, Mady C, et al. Beneficial effects of enalapril on the diastolic ventricular function in Chagas myocardiopathy. Arq Bras Cardiol 60:273-8, 1993.
24. Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res 43:838-49, 1999.
25. Han CJ, Liu JT, Li M, et al. Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway. Inflamm Res 61:1031-7, 2012.
26. Peng N, Liu JT, Gao DF, Lin R, Li R. Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 193:292-8, 2007.
27. Peng N, Liu JT, Guo F, Li R. Epigallocatechin-3-gallate inhibits interleukin-6- and angiotensin II-induced production of C-reactive protein in vascular smooth muscle cells. Life Sci 86:410-5, 2010.
28. Li M, Liu JT, Pang XM, Han CJ, Mao JJ. Epigallocatechin-3-gallate inhibits angiotensin II and interleukin-6-induced C-reactive protein production in macrophages. Pharmacol Rep 64:912-8, 2012.
29. Zhang R, Zhang YY, Huang XR, et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 55:953-60, 2010.
30. Bonny A, Lellouche N, Ditah I, et al. C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia. Res Pract pii: 919783, 2010.
31. Mano Y, Anzai T, Kaneko H, et al. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ J 75:1717-27, 2011.
32. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 7:748-54, 2005.
33. Aggelopoulos P, Chrysohoou C, Pitsavos C, et al. Comparative value of simple inflammatory markers in the prediction of left ventricular systolic dysfunction in postacute coronary syndrome patients. Mediators Inflamm 2009:826297, 2009.
34. Arruda-Olson AM, Enriquez-Sarano M, Bursi F, et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am J Cardiol 105:917-21, 2010.
35. Swiatkiewicz I, Kozinski M, Magielski P, et al. Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. Inflamm Res 61:725-34, 2012.
36. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol 109:248-56, 2006.